Harry Erba, MD, PhD:So, next we’re going to discuss a 67-year-old woman who goes to her primary care physician with a number of symptoms. She has fatigue, she has abdominal fullness, she has night sweats, and she has been losing weight. She has lost 17 pounds. On her past medical history, she just has hypertension on physical exam. Her spleen tip is palpable, about 7 cm below the left costal margin. Nothing else on exam. In terms of her blood count, she’s anemic with a hemoglobin of 9.2. She has a normal platelet count of 189,000 and she has leukocytosis with a white-blood cell count of 19,000.
So, at that point, you know that the patient has leukocytosis anemia and a big spleen. There’s a very broad differential diagnosis here. And looking at the peripheral blood smear can be very helpful because this could be a patient with chronic lymphocytic leukemia, mantle cell lymphoma, or marginal zone lymphoma. So, lymphomas can present like this. Even hairy cell leukemia can present like this. And so, the peripheral blood smear might be very helpful with that leukocytosis if there are a lot of lymphocytes there and you can perform flow cytometry on the peripheral blood to try to ascertain the diagnosis. Evidently, that was likely not the case because she has a bone marrow biopsy, and the bone marrow biopsy shows class 3, or grade 3, fibrosis in the marrow, myelofibrosis. They do immunostains for CD34 and CD117 and find 1.2% blast in the marrow, and they do a molecular analysis showing that the disease in the marrow is positive for substitution of missense mutation inJAK2called the V617Fmutation. So, the final diagnosis is primary myelofibrosis.
Transcript edited for clarity.
March 2017
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More